Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer

IMPORTANCE: Patients with cancer undergoing treatment are at high risk of COVID-19 following SARS-CoV-2 infection; however, their ability to produce an adequate antibody response to messenger RNA SARS-CoV-2 vaccines is unclear. OBJECTIVE: To evaluate rates of antispike (anti-S) antibody response to...

Descripción completa

Detalles Bibliográficos
Autores principales: Massarweh, Amir, Eliakim-Raz, Noa, Stemmer, Amos, Levy-Barda, Adva, Yust-Katz, Shlomit, Zer, Alona, Benouaich-Amiel, Alexandra, Ben-Zvi, Haim, Moskovits, Neta, Brenner, Baruch, Bishara, Jihad, Yahav, Dafna, Tadmor, Boaz, Zaks, Tal, Stemmer, Salomon M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164144/
https://www.ncbi.nlm.nih.gov/pubmed/34047765
http://dx.doi.org/10.1001/jamaoncol.2021.2155

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164144/
https://www.ncbi.nlm.nih.gov/pubmed/34047765
http://dx.doi.org/10.1001/jamaoncol.2021.2155

Ejemplares similares